Sosei Group Earnings Call Marks Cautious Transition

Sosei Group Corporation ((JP:4565)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sosei Group’s latest earnings call painted a cautious but hopeful picture for investors. Management highlighted robust commercial momentum in Japan and the broader APAC region, alongside tangible progress in its drug pipeline, yet these positives were offset by sizeable operating losses, falling milestone income, and restructuring costs that underscore a transitional year.

Revenue Growth Masked by Changing Mix

Total revenue in FY2025 edged up to JPY 29.6 billion from JPY 28.8 billion, a modest 2.8% increase that looks less impressive once the shift in revenue mix is considered. Higher product sales were partly offset by weaker milestone revenue, leaving the top line broadly flat despite operational gains in core franchises.

Product Sales Powered by PIVLAZ and QUVIVIQ

Product sales climbed 27.1% year on year to JPY 17.8 billion, driven mainly by PIVLAZ and QUVIVIQ supply and royalties. This strong commercial performance is central to Sosei’s strategy to rely less on volatile milestone payments and more on recurring, defensible revenue streams in Japan and APAC.

PIVLAZ Extends Market Leadership

PIVLAZ delivered JPY 13.5 billion in sales, growing about 7% and cementing its domestic leadership position. Market share surged from 34% in 2022 to 74% in 2025, with 25,470 patients treated since launch, giving Sosei a high‑quality cash‑generating asset to anchor its neurology and hospital‑focused portfolio.

QUVIVIQ Accelerates Off a Small Base

QUVIVIQ net sales jumped from JPY 1.3 billion to JPY 4.3 billion, a 224% surge that reflects rapid uptake and improved market access. The removal of a two‑week prescription cap and approval of a second API supplier should support an expected roughly 30% sales increase in FY2026, with management guiding to JPY 5–7 billion.

Commercial Unit Back in the Black

The commercial, pharma‑type business returned to core operating profitability, posting JPY 6.5 billion in core operating profit. This turnaround validates Sosei’s focus on building a profitable regional commercial platform, which management sees as a stabilizing counterweight to lumpier R&D and partnership revenues.

Pipeline and Partner Programs Advance

Sosei reported steady progress across both partnered and in‑house R&D assets, underscoring the value of its discovery engine. Neurocrine’s lead M4 agonist direclidine is now in Phase III with top‑line data expected by end‑2027, while Centessa’s ORX‑750 is moving toward a registrational‑stage program, and two wholly owned assets are Phase II ready and in licensing talks.

Encouraging Early Clinical Data

NXE’744, a gut‑restricted EP4 agonist, showed about 50% reduction in drug‑induced gut permeability with favorable local exposure and no worrying safety issues in interim data. NXE’149 demonstrated CNS penetration and cognitive or alertness signals in Phase I, while oncology candidate NXE’732 delivered two partial responses, adding optionality for future deals.

Late‑Stage Rare Disease Asset Bolsters Portfolio

Sosei in‑licensed vamorolone for Duchenne Muscular Dystrophy across Japan, Korea, Australia and New Zealand, adding a late‑stage rare disease product to its lineup. Management emphasized that roughly 70% of its target customers overlap with PIVLAZ, suggesting attractive sales synergies and efficient market entry once approved.

Operational Efficiency and Restructuring Drive

The company launched a broad efficiency program, including management changes, pipeline refocusing and post‑merger integration completion, alongside planned cost cuts of more than 10%. Leadership expects these actions, combined with IT and process improvements, to begin materially improving the P&L in the second half of FY2026.

Milestone Revenue Drops Sharply

Milestone income fell to JPY 7.9 billion from JPY 11.2 billion, a near 30% decline mainly due to the absence of last year’s large partner payments. This highlights the inherent volatility of deal‑driven revenue and reinforces why Sosei is pushing to deepen its recurring product base and diversify its income sources.

Heavy Operating Losses Highlight Transition

Despite commercial success, core operating profit slipped slightly negative at JPY -0.4 billion, while IFRS operating loss widened to JPY -8.4 billion, with an even larger deficit when all special items are included. A JPY 4.6 billion charge tied to revised bond terms further weighed on results, underscoring the cost of repositioning the business.

R&D Investment Adds Near‑Term Pressure

R&D spending rose by JPY 2.7 billion as Sosei ramped clinical development and accelerated investment in obesity and metabolic programs. While this deepens the pipeline and long‑term value potential, it also contributed to platform‑side losses and raises the bar for future monetization via partnerships or approvals.

One‑Off Charges Hit FY2025 Profitability

The year’s reported loss was also shaped by JPY 1.8 billion in one‑off costs linked to structural reforms and business rebuilding, alongside impairments on selected assets. These non‑recurring items are framed as the necessary cost of reshaping Sosei’s portfolio and operations for a leaner, more focused future.

U.K. Discovery Platform Under Review

Management was candid that its U.K. discovery operations need a sharper focus and tougher capital discipline after failing to close a new high‑value partnership in FY2025. This unit, once the core growth engine, now faces restructuring as Sosei seeks to align investment with clearer monetization paths and partner demand.

BD Milestone Visibility Remains Limited

Executives stressed that business development milestones are inherently uncertain and largely driven by partners’ timelines and decisions. FY2026 guidance therefore embeds a conservative assumption of around JPY 2.5 billion in platform milestones, with any upside from additional BD deals treated as aspirational rather than baked into forecasts.

Regulatory and Data Risks Around New Assets

For vamorolone, Sosei still faces regulatory uncertainty over whether local authorities will require bridging data or additional trials before approval, which could delay launch or add costs. More broadly, tighter pricing and regulatory scrutiny in key markets are pushing partners to demand stronger data packages, raising the bar for future out‑licensing.

Cost‑Cut Timing Creates Execution Risk

Although SG&A fell by about JPY 800 million, or 4–5%, the company acknowledged that further cuts must be paced carefully to avoid impairing operations. Management expects most benefits from restructuring and digital initiatives to emerge only in the second half of FY2026, creating a near‑term timing gap versus its profitability ambitions.

Challenging Market Backdrop for Deals

Investors raised concerns that the out‑licensing environment has become tougher, with partners asking for more robust and later‑stage data before committing to significant upfront payments. This dynamic could extend timelines and increase costs for Sosei to strike large BD agreements, even as its Phase II‑ready assets attract interest.

Guidance Signals Ambitious FY2026 Turnaround

Management set aggressive FY2026 goals, including net product sales above JPY 19.5 billion for PIVLAZ and QUVIVIQ and achieving full‑year IFRS and core operating profitability with more than 10% total cost reduction. The company also aims to break even on its discovery platform, sign high‑value BD deals, out‑license its Phase II–ready assets, and launch at least one new partner Phase II trial, with benefits weighted to H2 FY2026.

Sosei’s call ultimately framed FY2025 as a year of groundwork rather than delivery, with strong commercial trends and a maturing pipeline offset by losses, volatile milestones and execution risk. For investors, the story now hinges on whether management can convert its cost‑cut plans, BD ambitions and regulatory milestones into the IFRS profitability it targets for FY2026 and beyond.